All In Biotech

NDA 022113 · Haleon US Holdings

Advil Allergy and Congestion Relief

Chlorpheniramine Maleate, Ibuprofen, Phenylephrine Hydrochloride · Oral · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 20, 2026Latest source record: Nov 23, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Dec 21, 2011

Approved uses

2

Original approval plus efficacy supplements

Registered trials

53

11 Phase 3, 4 recruiting

FAERS reports

576

31 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 3, 2025.

Uses temporarily relieves these symptoms associated with the common cold or flu: headache fever minor body aches and pains nasal congestion runny nose sinus pressure sneezing reduces swelling of the nasal passages temporarily restores freer breathing through the nose

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ADVIL ALLERGY AND CONGESTION RELIEF · CHLORPHENIRAMINE MALEATE 4MG; IBUPROFEN 200MG; PHENYLEPHRINE HYDROCHLORIDE 10MG · TABLET, ORAL · Over-the-counter
  • ADVIL MULTI-SYMPTOM COLD & FLU · CHLORPHENIRAMINE MALEATE 4MG; IBUPROFEN 200MG; PHENYLEPHRINE HYDROCHLORIDE 10MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Chlorpheniramine" as an intervention, any sponsor and status, largest first.

All 53 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective179
  • product use in unapproved indication99
  • drug effective for unapproved indication89
  • somnolence50
  • feeling abnormal28
  • drug effect incomplete18
  • therapeutic product effect incomplete18
  • dizziness17
  • therapeutic response unexpected16
  • dyspnoea15
  • fatigue14
  • incorrect dose administered14

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20126
201344
201452
2015114
201641
201717
201817
201934
202041
202144
202285
202359
202413
20256
20263

Recalls

1 FDA enforcement reports for this application.

  • Mar 16, 2020 · Class II · Terminated

    Labeling: Lacks Warning or Rx Legend- Certain lots does not include required safety warning information in the Drug Facts Panel.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 246 on PubMed

Sponsor: Haleon US Holdings · Also marketed as Advil Multi-Symptom Cold & Flu

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.